


Corporate Information

Background

Newron Pharmaceuticals S.p.A is a biopharmaceutical company focused on developing novel therapies for diseases of the Central Nervous System and pain. The company is based in Bresso, Italy, with additional clinical development operations in Basle, Switzerland, and is publicly-traded on the SWX Swiss Exchange under the symbol NWRN.



Product Pipeline

Newron has established a late-stage product pipeline including its lead compound, safinamide, which is currently in phase III development for the treatment of early and mid to late stage Parkinson's disease (PD) with Merck Serono, and ralfinamide, currently undergoing phase II trials for neuropathic and post surgical (dental) pain.

currently undergoing phase II trials for neuropathic and post surgical (dental) pain.

Safinamide:

- A unique molecule with a novel dual mechanism of action based on the enhancement of the dopaminergic function (through potent reversible inhibition of MAO-B and of dopamine uptake) and reduction of glutamatergic activity by inhibiting glutamate release
- Results of a six month phase III trial (2006) as adjunctive treatment to dopamine agonists in early

PD demonstrated a positive effect in motor symptoms and activities of daily living, as well as an improvement in cognitive function while associated with good tolerability

- Recent results of the 12-month extension of the trial showed that the addition of safinamide does not cause any tolerability/safety risk when compared with dopamine agonist monotherapy. It also showed that, at a dose of 50 to 100 mg once daily, safinamide continues to provide sustained improvement of Parkinson's disease motor symptoms and may delay the time to intervention for therapeutic adjustments

Ralfinamide:


- An innovative therapeutic oral agent for neuropathic pain with potential in inflammatory pain
- Small molecule, part of a new chemical class with linear kinetics and excellent "drugability"
- Blocks ion channel subtypes implicated in pain transmission
- Long-lasting anti-allodynic and anti-hyperalgesic effects in models of neuropathic pain
- No development of tolerance on chronic dosing
- Clear evidence of efficacy in a phase II placebo controlled trial in patients with neuropathic pain

Drug Discovery

Newron's clinical pipeline is supported by a portfolio of early-stage proprietary compounds generated by its ion channel drug discovery platform.

		Lead	Preclinical	Phase I	Phase II	Phase III
Safinamide ⁽¹⁾	Adjunctive to dopamine agonist Early Stage Parkinson's disease	[Progress bar from Lead to Phase III]				
	Adjunctive to levodopa Mid to late Stage Parkinson's disease	[Progress bar from Lead to Phase III]				
Ralfinamide	Neuropathic pain	[Progress bar from Lead to Phase II]				
	Post surgical (dental) pain	[Progress bar from Lead to Phase II]				
Others	NW-3509 CNS-related disorders and pain	[Progress bar from Lead to Preclinical]				
	Ion Channel Programs CNS-related disorders and pain	[Progress bar from Lead]				

(1) Newron is undertaking Phase III trials with safinamide for the treatment of PD on behalf of its partner Merck Serono



Strategy

Newron's goal is to become a fully integrated biopharmaceutical company focused on the discovery, development and commercialisation of drugs for the treatment of CNS-related diseases and pain, originated from its internal discovery effort and from licensing deals.

Collaborations

In 2006, Newron signed an agreement with Serono (now Merck Serono) giving them exclusive worldwide rights to develop, manufacture and commercialise safinamide in PD, Alzheimer's disease (AD) and other therapeutic applications. The deal is worth up to \$200 million in upfront and milestone payments, plus royalties to Newron, and gives the company the option to co-promote safinamide in Italy and Spain.

Management


Newron's senior management has an average of 25 years of experience in developing and bringing to the market drugs for CNS diseases such as AD, PD, epilepsy, sleep disorders etc. In addition, senior executives from the pharmaceutical and life science venture capital industry serve on the board, chaired by Rolf Stahel.

- Luca Benatti, Chief Executive Officer, Director, Founder
- Stefan Weber, Chief Financial Officer
- Ravi Anand, Chief Medical Officer
- Carlos De Sousa, Chief Business Officer
- Stefano Rossetti, VP Development
- Marco Caremi, VP Strategic Marketing and Head of Legal Affairs
- Patricia Salvati, VP Discovery, Founder

Funding

From inception in 1999, Newron raised a total of €62.2m of equity from a group of international life science venture capital investors including 3i, Atlas Venture, Apax, HBM BioVentures, HBM BioCapital and TVM Capital.

In December 2006, Newron was floated on the SWX Swiss Exchange, raising €74.3m. The stock is covered by numerous premium life science analysts.



Contacts

For further information on Newron and its products, please visit www.newron.com or contact:

Media

Italy

Luca Benatti - CEO
Phone: +39 02 6103 4 626

UK/Global media

Julia Phillips
Financial Dynamics
Phone: +44 (0) 20 7269 7187

Switzerland

Martin Meier-Pfister
The Investor Relations Firm AG
Phone: +41 43 244 81 40

Investors and analysts

Stefan Weber – CFO
Phone: +39 02 6103 46 30

